NuCana (NCNA) Competitors

NuCana (NASDAQ:NCNA) and Viracta Therapeutics (NASDAQ:VIRX) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their valuation, earnings, dividends, institutional ownership, profitability, analyst recommendations, risk and media sentiment.

Is NCNA or VIRX more profitable?

NuCana's return on equity of -680.75% beat Viracta Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
NuCana	N/A	-680.75%	-214.07%
Viracta Therapeutics	N/A	-1,899.61%	-114.21%

Which has more volatility & risk, NCNA or VIRX?

NuCana has a beta of 1.4, indicating that its stock price is 40% more volatile than the S&P 500. Comparatively, Viracta Therapeutics has a beta of 1.06, indicating that its stock price is 6% more volatile than the S&P 500.

Do analysts prefer NCNA or VIRX?

NuCana currently has a consensus price target of $5,000.00, indicating a potential upside of 145,248.84%. Viracta Therapeutics has a consensus price target of $1.13, indicating a potential upside of 11,403.07%. Given NuCana's higher probable upside, research analysts plainly believe NuCana is more favorable than Viracta Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
NuCana	0 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.50
Viracta Therapeutics	0 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.50

Which has higher valuation and earnings, NCNA or VIRX?

Viracta Therapeutics is trading at a lower price-to-earnings ratio than NuCana, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
NuCana	N/A	N/A	-$24.28M	-$646.16	-0.01
Viracta Therapeutics	N/A	N/A	-$51.06M	-$1.10	-0.01

Does the media prefer NCNA or VIRX?

In the previous week, NuCana had 3 more articles in the media than Viracta Therapeutics. MarketBeat recorded 4 mentions for NuCana and 1 mentions for Viracta Therapeutics. NuCana's average media sentiment score of 0.75 beat Viracta Therapeutics' score of 0.00 indicating that NuCana is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
NuCana	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Viracta Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Do institutionals & insiders believe in NCNA or VIRX?

44.0% of NuCana shares are owned by institutional investors. Comparatively, 31.4% of Viracta Therapeutics shares are owned by institutional investors. 31.2% of NuCana shares are owned by insiders. Comparatively, 10.7% of Viracta Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Summary

NuCana beats Viracta Therapeutics on 9 of the 11 factors compared between the two stocks.